CapForce News and Activities
Presence
Headquarters: United States (USA)
Acquisition, funding and merger involving CapForce.
- OpGen has changed its company name to CapForce (posted on March 3 2026).
- CapForce is now listed under ticker CFOR. (posted on March 2 2026).
Executives
View the org chart displaying its 10 main executives
Most searched biographies at CapForce
Popular executive movements at CapForce
- John Tan who was Chief Executive Officer, Chairman and Director, becomes Chairman of the Board (posted on December 9 2025).
- Christian-Laurent Bonte has joined the company as Chief Executive Officer (posted on December 9 2025).
Create your alert
to follow the executive moves at CapForce.
Biotechnology
CapForce has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
- RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
- Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Popular contacts in Biotechnology
News
Press releases by CapForce
- OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time | OpGen, Inc.
- OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven | OpGen, Inc.
- OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update | OpGen, Inc.
- OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel | OpGen, Inc.
- OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients | OpGen, Inc.
- OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine | OpGen, Inc.
- OpGen Reports First Quarter 2022 Financial Results and Provides Business Update | OpGen, Inc.
- OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time | OpGen, Inc.
- OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment | OpGen, Inc.
- Press Releases | OpGen, Inc.
- View more press releases Close
Social media about CapForce
- CapForce on Wikipedia, Google News & Yahoo Finance
- CapForce on LinkedIn, X (Twitter) & YouTube
